GLP-1/Weight Loss

A new study reveals the thriving, high-risk market for compounded weight-loss drugs. Even after FDA shortages ended, some clinics use unregulated suppliers.

VST Capital’s Atlas Healthcare Fund is posting staggering returns by ignoring financial models and reading lab reports. Is this the future of investing?

With its MASH drug Rezdiffra a certified blockbuster, Madrigal's upcoming Q2 report will reveal if its meteoric rise can be sustained against new rivals.

Beyond GLP-1, Boehringer Ingelheim’s new drug targets the brain's hunger signals, a calculated move in the high-stakes race for obesity treatment.

A new watchdog emerges as millions use unapproved GLP-1 drugs, many believing they're FDA-approved. How a shortage solution became a risky shadow market.

MindRank's AI platform propelled a GLP-1 drug to Phase III in record time. Its new $52M funding aims to prove this isn't a one-off, but a revolution.

Rani Therapeutics partners with PegBio, betting its drug-injecting capsule can unlock novel oral obesity therapies and challenge market giants.

A new partnership between Sam's Club and Weight Watchers makes holistic health more accessible, especially for those on GLP-1s. Is this the future of retail?

As India confronts a metabolic health crisis, a new care paradigm is emerging. Ajanta Pharma's latest move signals a larger trend: the future is not just a pill, but a personalized, digital ecosystem.

As GLP-1 drugs surge in popularity, one company is betting on a new model for seniors that pairs prescriptions with strength training to fight muscle loss.

A massive fitness study reveals success isn't about willpower, but a network of coaching, community, and tech. The most effective users? Adults over 60.

With a new ADC expert as CMO, Corbus Pharmaceuticals is advancing its dual pipeline. This move signals a critical phase for its cancer drug and obesity therapy.

New data reveals a deep divide in who can access revolutionary weight-loss drugs, exposing a market that is both booming and profoundly under-penetrated.

As lawsuits allege a link between blockbuster weight-loss drugs like Ozempic and irreversible blindness, a critical question emerges: Who guards our health?

Millions of older Americans can now access the popular weight-loss drug Wegovy for a $50 copay, a temporary move that could reshape healthcare policy and the pharma market.

A new report reveals a massive strategic shift in obesity care. Pharma giants are pouring billions into FGF21, a new drug class aiming beyond weight loss.

UFC GYM's new PWR Clinics signal a tectonic shift in the wellness industry. Is this the future of fitness or a high-stakes bet on a regulatory minefield?

As demand for its blockbuster drugs soars, Novo Nordisk turns to India's Shantha Biologics in a strategic deal that highlights a global supply chain shift.

Health Canada's approval of a generic Wegovy promises to slash costs and expand access, shifting the landscape for patients and the healthcare system.

As pharma giants battle with blockbuster drugs, one company is betting on a simple, non-systemic hydrogel. Is this the future of weight management?